Master Alliance Provisions Guide (MAPGuide)

Alnylam Pharmaceuticals – University of British Columbia- AlCana Technology, Sponsored Research Agreement

  • Equitable Access | Ensuring continuity

<p><em><strong>Definitionsstrong>em>p>
<p><b>“Related Partyb><span style=”fontweight: 400;”>means, with respect to (a) Alnylam, Alnylams Affiliates and its Sublicensees other than Tekmira and Protiva; (b) Tekmira, Tekmiras Affiliates and its Sublicensees other than Alnylam; and (c) Protiva, Protivas Affiliates and its Sublicensees.span>p>
<p><span style=”textdecoration: underline;”><b>8. Collaboration IPb>span>p>
<p><b>8.3 Diligenceb><span style=”fontweight: 400;”><strong>.strong> Alnylam shall use <a href=”#kt“>Commercially Reasonable Effortsa> to research, develop and commercialize a Licensed Product in the Field of Use. For purposes of this Section 8.3, the efforts of Alnylams Related Parties shall also be considered the efforts of Alnylam. Alnylam will be considered to have failed to meet its obligations to use Commercially Reasonable Efforts in the event that any of the following occur:span>p>
<p style=”paddingleft: 25px;”><span style=”fontweight: 400;”>(a) [**] formulation within [**] years after [**]; orspan>p>
<p style=”paddingleft: 25px;”><span style=”fontweight: 400;”>(b) [**] within [**] years after [**] covering at least [**].span>p>
<p><span style=”fontweight: 400;”>In the event of a failure by Alnylam to meet its obligations under subsections (a) or (b) above, the Parties will discuss Alnylams failure. If the reason for failure was the result of some factor outside Alnylams reasonable control and that such failure did not result from a lack of due diligence on Alnylams part, then the Parties will discuss a reasonable extension to the timelines set forth in (a) and/or (b) above. If Alnylam is unable to convince both AlCana and UBC that the reason for failure was the result of some factor outside Alnylams reasonable control and that such failure did not result from a lack of due diligence on Alnylams part, then UBC shall have the right to convert the Tekmira License to a nonexclusive license in accordance with the procedures set forth in <span style=”textdecoration: underline;”><a href=”https://ghiaa.org/provision_document/alnylampharmaceuticalsuniversityofbritishcolumbiaalcanatechnologysponsoredresearchagreement16/” target=”_blankrel=”noopener“>Section 10.2.2a>span>, and AlCana shall have, without further act by UBC, an irrevocable, perpetual, royaltyfree, worldwide, nonexclusive license under the <span style=”textdecoration: underline;”><a href=”https://ghiaa.org/provision_document/alnylampharmaceuticalsuniversityofbritishcolumbiaalcanatechnologysponsoredresearchagreement/” target=”_blankrel=”noopener“>AlCana Collaboration IPa>span>. All other terms and conditions of this Agreement and the Supplemental Agreement shall remain in full force and effect.span>p>